Why are benzodiazepines not recommended for a bipolar patient, particularly if there is current or past suicidal ideation?

Why Benzodiazepines Are Not Recommended in Bipolar Disorder with Suicidal Ideation

Benzodiazepines should be avoided in bipolar patients with current or past suicidal ideation because they increase suicide risk, impair self-control, and carry high lethality in overdose. 1, 2

Primary Safety Concerns

Increased Suicide Risk

• Benzodiazepine prescriptions of ≥30 days supply are associated with a 58% increased risk of suicide (HR=1.58) in patients with bipolar disorder, even after controlling for clinical and demographic factors. 2
• The majority of studies demonstrate that benzodiazepines cause an overall increase in the risk of attempting or completing suicide across various populations. 3
• Among Veterans Health Administration patients with bipolar disorder, benzodiazepine receipt was one of the strongest predictors of suicide mortality over a 5-year follow-up period. 2

Mechanisms of Prosuicidal Effects

• Benzodiazepines may reduce self-control and disinhibit some individuals, leading to increased aggression and suicide attempts. 1
• Possible mechanisms include increases in impulsivity or aggression, rebound or withdrawal symptoms, and toxicity in overdose. 3
• Benzodiazepines can cause paradoxical reactions—including agitation and disinhibition—in approximately 10% of patients, which may precipitate suicidal behavior. 4

High Lethality in Overdose

• Phenobarbital and benzodiazepines have high lethal potential when taken in overdose, making them particularly dangerous for suicidal patients. 1
• Clinicians should be cautious about prescribing medications that may reduce self-control, such as benzodiazepines and phenobarbital, especially in patients with suicidal ideation. 1

Guideline Recommendations

Explicit Warnings Against Use

• The American Academy of Child and Adolescent Psychiatry explicitly recommends that benzodiazepines and phenobarbital should not be used as chronic (standing) medications in adolescents with bipolar depression and suicidality because they can impair self-control and possess high lethal potential in overdose. 4
• The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommends benzodiazepines only as third-line therapy, and their use should be avoided in patients with comorbid bipolar disorder, posttraumatic stress disorder, and substance use disorders. 5

Specific Clinical Contexts

• Benzodiazepine use should in general be avoided for all patients if possible, based upon current clinical research. 5
• While benzodiazepines may be useful alternatives to antipsychotics for severe agitated, repetitive, and combative behaviors, they should be time-limited (days to weeks) to avoid tolerance and dependence. 4

Evidence from Bipolar Populations

Worse Outcomes in Comorbid Conditions

• In the STEP-BD cohort, benzodiazepine use at baseline was significantly higher in patients with comorbid bipolar disorder and PTSD (compared to bipolar disorder alone), and benzodiazepine use was associated with poorer quality of life despite a small improvement in depression symptom scores. 6
• Those with comorbid PTSD experienced higher levels of mania and depression symptoms and lower functioning and quality of life compared to bipolar disorder alone, irrespective of pharmacotherapy treatment including benzodiazepines. 6

Concurrent Use with Other Medications

• Concurrent use of opioids and benzodiazepines significantly elevated the risk of suicide attempts and intentional self-harm. 7
• Benzodiazepines and opioids both cause central nervous system depression and can decrease respiratory drive, with concurrent use associated with a near quadrupling of risk for overdose death. 1

Withdrawal and Discontinuation Risks

Dangerous Withdrawal Syndrome

• Abrupt benzodiazepine withdrawal can cause rebound anxiety, hallucinations, seizures, delirium tremens, and, in rare cases, death. 1
• Because of greater risks of benzodiazepine withdrawal relative to opioid withdrawal, when patients receiving both require tapering, it might be safer to taper opioids first. 1
• A commonly used tapering schedule is a reduction of the benzodiazepine dose by 25% every 1–2 weeks, with cognitive behavioral therapy increasing tapering success rates. 1

Safer Alternatives for Anxiety Management

Non-Benzodiazepine Pharmacologic Options

• If benzodiazepines prescribed for anxiety are tapered or discontinued, evidence-based psychotherapies (e.g., CBT) and/or specific antidepressants or other nonbenzodiazepine medications approved for anxiety should be offered. 1
• Buspirone 5mg twice daily (maximum 20mg three times daily) may be useful for mild to moderate anxiety, though it takes 2-4 weeks to become effective. 4

Psychosocial Interventions

• Cognitive-behavioral therapy should be considered as the primary non-pharmacological intervention for comorbid anxiety symptoms in bipolar disorder. 4
• Interpersonal, cognitive behavioral, and relaxation therapy are effective for the treatment of anxiety symptoms, especially emotional experiences, in patients who are euthymic. 5

Common Clinical Pitfalls

• Prescribing benzodiazepines for short-term use often leads to long-term dependence, with prescriptions of ≥30 days supply conferring the highest suicide risk. 2
• Failing to recognize that benzodiazepines may worsen mood instability and increase impulsivity in bipolar patients, particularly those with suicidal ideation. 1, 3
• Not implementing third-party medication supervision and limited prescription quantities when any potentially lethal medication must be prescribed to suicidal patients. 4